Filing Flows › Bristol Myers Squibb (BMY) › Q2 2026 › vs Q1 2026
Bristol Myers Squibb (BMY) Q2 2026 vs Q1 2026 (quarter over quarter)
Bristol Myers Squibb's revenue rose $1.5B (+13%) from $11.5B in Q1 2026 to $13.0B in Q2 2026. Operating margin 31.5% against 28.2% (+3.3 pts).
Bristol Myers Squibb, Q2 2026: revenue $13.0B (+6% year over year), operating margin 31.5%, net earnings $3.3B, operating cash flow $3.4B. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Operating margin | 31.5% | 28.2% | +3.3 pts |
| Net margin | 25.6% | 23.3% | +2.3 pts |
| Free cash flow margin | 23.8% | 6.6% | +17.2 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $13.0B | $11.5B | $1.5B | +13% |
| Operating profit | $4.1B | $3.2B | $847M | +26% |
| Costs & expenses | $8.9B | $8.2B | $637M | +8% |
| Pre-tax earnings | $4.1B | $3.2B | $846M | +26% |
| Cost of revenue | $3.7B | $3.4B | $305M | +9% |
| Research & development | $3.0B | $2.6B | $310M | +12% |
| SG&A | $1.8B | $1.6B | $209M | +13% |
| Other operating costs | $376M | $563M | −$187M | -33% |
| Net earnings | $3.3B | $2.7B | $638M | +24% |
| Income tax | $770M | $561M | $209M | +37% |
| Depreciation & amortization | $594M | $594M | $0 | 0% |
| Share-based compensation | $135M | $146M | −$11.0M | -8% |
| Working capital & other | $652M | $2.3B | −$1.7B | -72% |
| Operating cash flow | $3.4B | $1.1B | $2.3B | +207% |
| Free cash flow (OCF − capex) | $3.1B | $757M | $2.3B | +308% |
| Capital expenditures | $305M | $347M | −$42.0M | -12% |
Questions
How much did Bristol Myers Squibb's revenue grow quarter over quarter in Q2 2026?
Bristol Myers Squibb's revenue rose $1.5B (+13%) from $11.5B in Q1 2026 to $13.0B in Q2 2026. Operating margin 31.5% against 28.2% (+3.3 pts).